MX2023005940A - Radioinmunoterapia con her3 para el tratamiento de canceres solidos. - Google Patents

Radioinmunoterapia con her3 para el tratamiento de canceres solidos.

Info

Publication number
MX2023005940A
MX2023005940A MX2023005940A MX2023005940A MX2023005940A MX 2023005940 A MX2023005940 A MX 2023005940A MX 2023005940 A MX2023005940 A MX 2023005940A MX 2023005940 A MX2023005940 A MX 2023005940A MX 2023005940 A MX2023005940 A MX 2023005940A
Authority
MX
Mexico
Prior art keywords
sup
her3
radioimmunotherapy
treatment
solid cancers
Prior art date
Application number
MX2023005940A
Other languages
English (en)
Spanish (es)
Inventor
Dale L Ludwig
Eileen Geoghegan
Sandesh Seth
Paul Diamond
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/056259 external-priority patent/WO2022087416A1/fr
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of MX2023005940A publication Critical patent/MX2023005940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2023005940A 2020-11-20 2021-11-22 Radioinmunoterapia con her3 para el tratamiento de canceres solidos. MX2023005940A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063116225P 2020-11-20 2020-11-20
US202063118181P 2020-11-25 2020-11-25
US202163226699P 2021-07-28 2021-07-28
US202163250725P 2021-09-30 2021-09-30
PCT/US2021/056259 WO2022087416A1 (fr) 2020-10-22 2021-10-22 Combinaison de radioimmunothérapie et de blocage de cd47 dans le traitement du cancer
PCT/US2021/060370 WO2022109404A1 (fr) 2020-11-20 2021-11-22 Radioimmunothérapie de her3 pour le traitement de cancers solides

Publications (1)

Publication Number Publication Date
MX2023005940A true MX2023005940A (es) 2023-07-27

Family

ID=81709768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005940A MX2023005940A (es) 2020-11-20 2021-11-22 Radioinmunoterapia con her3 para el tratamiento de canceres solidos.

Country Status (8)

Country Link
EP (1) EP4247430A1 (fr)
JP (1) JP2023550462A (fr)
KR (1) KR20230128271A (fr)
AU (1) AU2021382717A1 (fr)
CA (1) CA3199259A1 (fr)
IL (1) IL303030A (fr)
MX (1) MX2023005940A (fr)
WO (1) WO2022109404A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017008169A1 (fr) * 2015-07-15 2017-01-19 Zymeworks Inc. Constructions bispécifiques de liaison à un antigène conjuguées à un médicament
JP2022515187A (ja) * 2018-12-21 2022-02-17 アクティニウム ファーマシューティカルズ インコーポレイテッド 癌の治療における放射免疫療法と免疫チェックポイント療法との組み合わせ

Also Published As

Publication number Publication date
KR20230128271A (ko) 2023-09-04
CA3199259A1 (fr) 2022-05-27
EP4247430A1 (fr) 2023-09-27
WO2022109404A1 (fr) 2022-05-27
JP2023550462A (ja) 2023-12-01
AU2021382717A1 (en) 2023-07-06
IL303030A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
King et al. Use of amifostine for cytoprotection during radiation therapy: a review
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
MX2009007597A (es) Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
Hansen 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies
JP2016515586A5 (fr)
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
MX2023005940A (es) Radioinmunoterapia con her3 para el tratamiento de canceres solidos.
MX2020006808A (es) Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral.
Bruckner et al. Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer
MX2020013883A (es) Tratamientos oncológicos con agentes de zinc.
Wong Total marrow irradiation: redefining the role of radiotherapy in bone marrow transplantation
WO2023028613A3 (fr) Radio-immunoconjugués ciblant la phosphatidylsérine destinés à être utilisés dans le traitement du cancer
WO2007082742A8 (fr) Thérapie combinée du cancer par perfusion d'organes isolés
Nakai et al. Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer
WO2010057596A3 (fr) Nouvelle thérapie et médicament utilisant des ligands d'intégrine pour traiter un cancer
Moro et al. Does concomitant chemoradiotherapy influence cosmetic outcome in conservative treatment of breast cancer?
Vo et al. Safety and efficacy of yttrium-90-labeled anti-CD45 antibody (90Y-DOTA-BC8) followed by a standard reduced-intensity hematopoietic stem cell transplant (HCT) regimen for patients with refractory/relapsed leukemia or high-risk myelodysplastic syndrome (MDS)
MXPA01009458A (es) Cisplatina radioactiva en el tratamiento de cancer.
Jia et al. Clinical study on Lobaplatin combined with 5-Fu and concurrent radiotherapy in treating patients with inoperable esophageal cancer
Quackenbush et al. Regression of a fungating tumor after hypofractionated radiation therapy in a patient with metastatic breast cancer
Marcu The role of amifostine in the treatment of head and neck cancer with cisplatin‐radiotherapy
Wang et al. Efficacy of brachytherapy concomitant with chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in unresectable head and neck squamous cell carcinoma
Yoon et al. Basic concepts of clinical radiation oncology
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.